Login

NON-SUBSCRIBER OPTIONS
FREE TRIAL   |   NEWSSTAND

Providing a steady flow of breaking news, analysis, news briefs, document texts and more, all designed to ensure you have the best, most complete information available anywhere about what’s happening in drug pricing.

Unlike commercial and Medicaid plans, Medicare Part D plans favor high list-price drugs when identical low list-price drugs are available, according to Drug Channels CEO Adam Fein, who analyzed newly released data from IQVIA on market share of hepatitis C drugs.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.